Haooubo: The Phase III clinical trial of MM09 sublingual spray has completed the enrollment of the first group of subjects.

Hoohob announcement, recently, the company received notification from its wholly-owned subsidiary Shanghai Hoohob Biopharmaceutical Co., Ltd that the joint application for desensitization drug MM09 sublingual spray Phase III clinical trial by Shanghai Hoohob and Inmunotek was successfully completed with the enrollment of the first batch of subjects. As a leading enterprise in the field of allergy diagnosis, the company is engaged in allergen desensitization therapy business, which effectively fills the domestic gap and promotes the "diagnosis and treatment integration" of the company's business. It achieves a strong synergistic effect between allergy diagnosis and desensitization therapy, providing more convenient and efficient desensitization treatment solutions for domestic allergic patients.